CD274 and hepatocellular carcinoma: An EZH2 inhibitor (DZNep) and DNMT1 c (5-azacytidine) can augment anti-PD-L1 immunotherapy for HCC by increasing the release of the chemokines CXCL9 and CXCL10, which stimulate T cell trafficking into the TME.